These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 34151519)

  • 1. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
    Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.
    Janelidze S; Barthélemy NR; Salvadó G; Schindler SE; Palmqvist S; Mattsson-Carlgren N; Braunstein JB; Ovod V; Bollinger JG; He Y; Li Y; Raji CA; Morris JC; Holtzman DM; Ashton NJ; Blennow K; Stomrud E; Bateman RJ; Hansson O
    JAMA Neurol; 2024 Sep; 81(9):947-957. PubMed ID: 39068669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
    Palmqvist S; Stomrud E; Cullen N; Janelidze S; Manuilova E; Jethwa A; Bittner T; Eichenlaub U; Suridjan I; Kollmorgen G; Riepe M; von Arnim CAF; Tumani H; Hager K; Heidenreich F; Mattsson-Carlgren N; Zetterberg H; Blennow K; Hansson O
    Alzheimers Dement; 2023 Apr; 19(4):1204-1215. PubMed ID: 35950735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
    Rissman RA; Langford O; Raman R; Donohue MC; Abdel-Latif S; Meyer MR; Wente-Roth T; Kirmess KM; Ngolab J; Winston CN; Jimenez-Maggiora G; Rafii MS; Sachdev P; West T; Yarasheski KE; Braunstein JB; Irizarry M; Johnson KA; Aisen PS; Sperling RA;
    Alzheimers Dement; 2024 Feb; 20(2):1214-1224. PubMed ID: 37932961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
    Bali D; Hansson O; Janelidze S
    Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
    Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
    Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
    Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
    Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of β-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
    Cai Y; Shi D; Lan G; Chen L; Jiang Y; Zhou L; Guo T;
    Neurology; 2024 Apr; 102(7):e209205. PubMed ID: 38489560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.
    McCarter SJ; Lesnick TG; Lowe VJ; Rabinstein AA; Przybelski SA; Algeciras-Schimnich A; Ramanan VK; Jack CR; Petersen RC; Knopman DS; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Graff-Radford J
    J Alzheimers Dis; 2022; 87(4):1537-1547. PubMed ID: 35527558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.
    Palmqvist S; Janelidze S; Stomrud E; Zetterberg H; Karl J; Zink K; Bittner T; Mattsson N; Eichenlaub U; Blennow K; Hansson O
    JAMA Neurol; 2019 Sep; 76(9):1060-1069. PubMed ID: 31233127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.
    Guo T; Li A; Sun P; He Z; Cai Y; Lan G; Liu L; Li J; Yang J; Zhu Y; Zhao R; Chen X; Shi D; Liu Z; Wang Q; Xu L; Zhou L; Ran P; Wang X; Sun K; Lu J; Han Y
    Mol Neurodegener; 2024 Jul; 19(1):58. PubMed ID: 39080744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.
    Gonzalez-Ortiz F; Ferreira PCL; González-Escalante A; Montoliu-Gaya L; Ortiz-Romero P; Kac PR; Turton M; Kvartsberg H; Ashton NJ; Zetterberg H; Harrison P; Bellaver B; Povala G; Villemagne VL; Pascoal TA; Ganguli M; Cohen AD; Minguillon C; Contador J; Suárez-Calvet M; Karikari TK; Blennow K
    Alzheimers Dement; 2024 Feb; 20(2):1239-1249. PubMed ID: 37975513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.